Oxaliplatin, an Anticancer Agent, Causes Erectile Dysfunction in Rats due to Endothelial Dysfunction.

Area of Science:

• Urology
• Oncology
• Pharmacology

Background:

• Chemotherapy, including oxaliplatin (L-OHP), is a standard cancer treatment.
• Oxaliplatin (L-OHP) administration is associated with adverse effects, notably erectile dysfunction (ED).

Purpose of the Study:

• To investigate the impact of oxaliplatin (L-OHP) on erectile function in an animal model.
• To explore the underlying mechanisms of oxaliplatin-induced ED, focusing on endothelial function and nitric oxide (NO) pathways.

Main Methods:

• Male Wistar/ST rats were administered oxaliplatin (L-OHP) or a control solution intravenously for four weeks.
• Erectile function was assessed by measuring intracavernous pressure (ICP) and mean arterial pressure (MAP).
• Endothelial function, nitric oxide synthase (NOS) protein levels, and inflammatory markers were evaluated using tension studies and molecular analyses (Western blot, qRT-PCR).

Main Results:

• Oxaliplatin (L-OHP) treated rats exhibited significantly lower ICP:MAP ratios compared to controls.
• Reduced acetylcholine (ACh) response and lower endothelial NO synthase (eNOS) protein levels were observed in the L-OHP group.
• Increased expression of inflammatory biomarkers, including NADPH oxidase-1, p22phox, IL-6, and NF-κB, was noted in L-OHP treated rats.

Conclusions:

• Oxaliplatin (L-OHP) induces erectile dysfunction (ED) in rats, primarily through endothelial dysfunction and reduced nitric oxide (NO) bioavailability.
• The findings suggest oxaliplatin (L-OHP) is a risk factor for ED in humans, highlighting potential therapeutic strategies for cancer survivors.